Longitudinal retinal phenotype and NEI VFQ-25-assessed vision-related quality of life in four Palestinian siblings with CFAP418 c.155+1G>A-related ciliopathy: a familial case series

Vision is often taken for granted, a seamless stream of light and color that allows us to navigate the world, recognize faces, and read the signs of daily life. When that stream is interrupted by a genetic condition, the disruption is not merely a loss of sight but a fundamental shift in how a person exists within their environment. In the realm of inherited eye diseases, scientists have long known that a single genetic error can cause the light-sensing cells in the retina to fail. These cells, which act as the eye's biological film, are supported by tiny, hair-like structures called cilia. When these cilia do not function correctly, the eye cannot maintain its health, leading to a slow, progressive blindness. For decades, doctors have struggled to categorize these conditions, sometimes labeling them as distinct diseases based on whether the center or the edges of vision failed first, or whether other body systems like the kidneys or limbs were involved. However, recent scientific thinking has begun to view these conditions not as separate entities, but as a single spectrum of illness caused by a broken cellular machine, where the specific symptoms depend on how the error plays out in each individual.

This perspective is the backdrop for a detailed look at a single Palestinian family, where four siblings share the same genetic mutation but experience the disease in slightly different ways. The researchers focused on a specific error in a gene called CFAP418, which provides instructions for building a protein essential for the health of those tiny cilia in the eye. While this gene has been linked to a broad range of symptoms, including extra fingers or toes and obesity, the full picture of how the disease moves through a family over time has remained unclear. By following these four adults, who were born to parents who are closely related, the study offers a rare, longitudinal view of how a shared genetic cause can lead to a shared path of vision loss, while still allowing for unique differences in how the body reacts.

The family consists of four adult siblings: two 28-year-old men who are identical twins, a 30-year-old brother, and a 26-year-old sister. All four carry two copies of the same genetic error, a specific change in their DNA that prevents the CFAP418 protein from working correctly. Despite sharing this exact genetic blueprint, their physical appearances diverge in one notable way. The twins were born with extra fingers on the outer side of their hands, a condition known as postaxial polydactyly. Their older brother and sister, however, have the typical number of fingers. This difference highlights a key finding of the study: while the genetic cause is identical, the way it manifests in the rest of the body can vary significantly, even between siblings.

The story of their vision loss follows a remarkably similar timeline, suggesting a predictable pattern of decline driven by the genetic error. For all four siblings, the trouble began in childhood with difficulty seeing in bright daylight and an aversion to light. As they grew into their teens, their vision for colors began to fade, and their ability to see fine details in the center of their sight started to deteriorate. It was not until their mid-to-late twenties that they began to struggle with seeing in the dark, a symptom known as night blindness, followed by a loss of vision at the edges of their sight. This sequence, starting with problems in bright light and color and moving toward night blindness and peripheral loss, points to a disease process that attacks the central, color-sensing cells first, before spreading to the cells that handle low light and wide-angle vision.

The severity of the condition varies among the siblings, reflecting the different stages of their individual journeys. The two twins, who both have the extra fingers, have reached a point where they can only count fingers held very close to their faces. Their eyes show clear signs of advanced damage, including a specific type of pigment clumping in the retina and a thinning of the outer layers where the light-sensing cells live. The 30-year-old brother, who does not have extra fingers, has lost all usable vision in his field of view and relies on a cane for movement. The 26-year-old sister, also without extra fingers, faces a similar future of blindness, with her vision already severely compromised. While their physical symptoms differ slightly, the trajectory of their eye disease is strikingly consistent, moving from early daylight struggles to a total loss of functional vision.

Beyond the clinical measurements, the study captures the profound impact of this vision loss on the siblings' daily lives. Using a standard questionnaire designed to measure how vision affects a person's ability to function, the researchers found that all four siblings scored very low, indicating a heavy burden on their quality of life. The scores ranged from 22.7 to 44.1 on a scale of zero to 100, where zero represents the worst possible vision-related function. For the sister, who is a mother, the loss of sight has complicated her ability to care for her children and manage household tasks. The twins, despite having excellent general health in other areas, face significant limitations in reading, navigating streets, and participating in social events. One brother, who has lost all vision, depends entirely on assistive technology and a cane to move through the world. These numbers and stories illustrate that the disease is not just a medical diagnosis but a force that reshapes a person's independence and role within their family.

The researchers also examined whether these siblings fit the classic definition of a syndrome called Bardet-Biedl, which typically involves a combination of vision loss, extra fingers, obesity, and kidney problems. The twins, with their vision loss and extra fingers, fit the modern genetic definition of this syndrome. However, the other two siblings, who lack the extra fingers and have different weight histories, do not fit the traditional clinical checklist perfectly. This discrepancy led the authors to argue that doctors should stop trying to force every patient into a rigid box based on a list of symptoms. Instead, they suggest that once a genetic cause like CFAP418 is found, the focus should shift to monitoring the specific needs of that individual, regardless of whether they have every classic symptom. The study explicitly states that the disease does not necessarily "convert" from one type to another, such as from a central vision problem to a peripheral one, but rather that these are different stages of the same underlying failure of the eye's cellular machinery.

A critical part of the study involved looking at the broader context of this specific genetic error. The mutation found in this family, a change in the DNA sequence at a specific spot, has been seen in other families in Jordan, where it also caused a wide variety of symptoms. This confirms that the mutation is not a unique discovery for this family, but rather a known cause of a broad spectrum of disease. The value of this report lies in its detailed comparison of four siblings living with the same error, providing a clear picture of how the disease progresses over time within a single family unit. The authors note that while they have a complete picture of the eyes, they lack information on the kidneys, which are often affected in similar conditions, highlighting an area where future care for these patients needs to be more thorough.

Ultimately, this case series serves as a reminder that genetic diseases are complex and personal. Even when four people share the exact same genetic mistake, their bodies may respond in ways that are similar in some respects and different in others. The study concludes that the best approach for families like this is to combine molecular diagnosis with careful, ongoing monitoring of the eyes and other body systems. It emphasizes the need for early genetic testing to unify years of changing medical labels and to provide families with a clear understanding of what to expect. By pairing this medical clarity with support for the daily challenges of living with vision loss, doctors can help patients navigate a future that, while challenging, is understood with greater precision and compassion. The work underscores that while the genetic error is fixed, the care required to manage its effects must be flexible, attentive, and deeply rooted in the lived experience of the patient.